Read more from Yash

Our industry faces numerous challenges related to scaling manufacturing processes for cell and gene therapies. Explore some key recommendations and potential solutions.

Yes indeed, CherryCircle just knocked out an additional round of seed financing. Combined with our last raise, brings our total fundraising to around $4.6M.

Today, the FDA issued temporary guidance on the resumption of normal manufacturing operations during the COVID-19 health emergency.

There is a consistent theme that comes up in the world of pharmaceutical process development and validation: a pervasive confusion around how ICH guidelines match up with quality-by-design principles.

See how our platform builds risk in discrete layers that are designed to be updated and managed throughout the development lifecycle thus capturing the evolution of risk.

This blog post series is intended to rationalize and standardize the risk assessment discussion to communicate strategies that provide consistency, objectivity, and risk understanding. Over the next few weeks, we’ll be sharing strategies and approaches that explain how to manage these situations.

While many industries have moved to adopt the latest technologies and practices to improve their operational efficiency and lower costs of production, the pharmaceutical industry has been slow to keep pace, especially with respect to manufacturing.

CherryCircle Software, Inc. announced today that Malia Lewin has joined its executive management team as Chief Business Officer. CherryCircle has developed the QbDVision® software platform.

We’re pleased to welcome aboard and introduce John Maguire as our new Director of Client Services. Joining us from Takeda in Lexington, MA, John comes with a deep background in biomanufacturing processes and the application of operational technologies to optimize these processes.